Advanced Search

    Technical Analysis for NRSN - NeuroSense Therapeutics Ltd.

    Grade Last Price % Change Price Change
    B 1.74 4.82% 0.08
    NRSN closed up 4.82 percent on Friday, March 24, 2023, on 2 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Up Flat
    Historical NRSN trend table...
    Date Alert Name Type % Chg
    Crossed Above 50 DMA Bullish 0.00%
    Bollinger Band Squeeze Range Contraction 0.00%
    BB Squeeze + Lower Band Touch Range Contraction 0.00%
    BB Squeeze Started Range Contraction 0.00%
    Lower Bollinger Band Touch Weakness 0.00%
    50 DMA Resistance Bearish 4.82%
    MACD Bearish Centerline Cross Bearish 4.82%
    Doji - Bullish? Reversal 4.82%
    Outside Day Range Expansion 4.82%
    Lower Bollinger Band Touch Weakness 4.82%
    Older End-of-Day Signals for NRSN ...

       Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

    Alert Time
    10 DMA Resistance about 14 hours ago
    60 Minute Opening Range Breakout about 14 hours ago
    Rose Above 10 DMA about 14 hours ago
    Up 5% about 14 hours ago
    Rose Above Previous Day's High about 15 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators Basic chart:

    Profile

    NeuroSense Therapeutics is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include ALS, Alzheimer's disease and Parkinson's disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients. Due to the complexity of neurodegenerative diseases, NeuroSense's strategy is to develop combined therapies targeting multiple pathways associated with these diseases.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biology Disease Neuroscience Alzheimer's Disease Parkinson's Disease Neurodegenerative Diseases Neurodegeneration Senescence Gladstone Institutes

    Is NRSN a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Mar 23 NeuroSense to Present at the ALS and Alzheimer's Disease at AD/PD™ 2023 Advances in Science & Therapy Conference
    Mar 22 NeuroSense Therapeutics GAAP EPS of -$1.07
    Mar 22 NeuroSense Announces Year End 2022 Financial Results and Provides Business Update
    Mar 16 NeuroSense Therapeutics to Participate in BIO-Europe Spring
    Mar 14 NEUROSENSE THERAPEUTICS LTD. TO PARTICIPATE IN RENMARK'S VIRTUAL NON-DEAL ROADSHOW SERIES ON, TUESDAY, MARCH 21 AND TUESDAY, MARCH 28, 2023
    Feb 13 NeuroSense CEO Recaps 2022 Achievements & Presents 2023 Catalysts
    Feb 10 Here's Why We're Watching NeuroSense Therapeutics' (NASDAQ:NRSN) Cash Burn Situation
    Feb 9 NeuroSense and QuantalX Collaborate to Improve Early Detection and Treatment of Neurodegenerative Diseases
    Feb 8 NeuroSense Receives Approval in Germany to Enroll Patients in its Phase 2b ALS Trial
    Feb 6 NeuroSense Expands its Phase 2b ALS PARADIGM Trial to Canada and Withdraws Protocol from U.S. IND to Align its Clinical Strategy with the FDA for a Potential Pivotal Phase 3 Study
    See more NRSN news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 5.2
    52 Week Low 1.075
    Average Volume 1,775,525
    200-Day Moving Average 1.78
    50-Day Moving Average 1.71
    20-Day Moving Average 1.76
    10-Day Moving Average 1.75
    Average True Range 0.13
    RSI 50.25
    ADX 17.91
    +DI 14.96
    -DI 18.22
    Chandelier Exit (Long, 3 ATRs) 1.65
    Chandelier Exit (Short, 3 ATRs) 1.94
    Upper Bollinger Bands 1.88
    Lower Bollinger Band 1.63
    Percent B (%b) 0.44
    BandWidth 14.07
    MACD Line 0.00
    MACD Signal Line 0.01
    MACD Histogram -0.0147
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.96
    Resistance 3 (R3) 1.94 1.85 1.93
    Resistance 2 (R2) 1.85 1.79 1.86 1.91
    Resistance 1 (R1) 1.79 1.75 1.82 1.81 1.90
    Pivot Point 1.70 1.70 1.71 1.71 1.70
    Support 1 (S1) 1.64 1.64 1.67 1.67 1.58
    Support 2 (S2) 1.55 1.60 1.56 1.57
    Support 3 (S3) 1.49 1.55 1.55
    Support 4 (S4) 1.52